Beijing, Shanghai, Boston, Jul 2, 2025 – Jacobio Pharma (1167.HK), a clinical-stage 
oncology company focusing on undruggable targets, today announced that it has completed the first patient dosage of Pan-KRAS inhibitor  (JAB-23E73) in the Phase I/IIa clinical study in the U.S. In parallel, the dose-escalation study in China is progressing as planned.
 
KRAS mutations represent one of the most common oncogenic alterations in tumors, occurring in approximately 23%-25% of cancer patients. The mutation frequency is particularly high in pancreatic cancer (~90%), colorectal cancer (~40%), and non-small cell lung cancer (~30%). An estimated 2.7 million newly diagnosed cancer patients worldwide are found to have tumor with KRAS mutations, underscoring the significant unmet need and the potential benefit of pan-KRAS inhibitors for this patient population.

JAB-23E73 demonstrates high selectivity for KRAS, effectively inhibiting both the active (“On”) and inactive (“Off”) states of KRAS, with no inhibition to HRAS or NRAS. As an oral KRAS inhibitor, JAB-23E73 has shown a favorable pharmacokinetic profile and promising anti-tumor activity in preclinical models.

About Jacobio 
Jacobio Pharma (1167.HK) is committed to providing breakthrough treatments for patients. With an induced allosteric drug discovery platform, the company’s core projects focus on the KRAS pathway. The company envisions becoming a global leader in research and development, fostering strategic partnerships to drive innovation. Jacobio’s  R&D centers are located in Beijing, Shanghai (China), and Boston (USA). Clinical trials are conducted at over 180 sites in China, more than 30 sites in the USA, and over 10 sites across several European countries.
For more information, please visit: http://www.jacobiopharma.com